Vinci Lifts 2023 Free Cash Flow Guidance After 3Q Revenue Rose
By Pierre Bertrand
Vinci backed its 2023 guidance and lifted its free cash flow outlook for the year after third-quarter revenue rose.
The French construction and infrastructure company said Thursday that revenue for the period was 18.27 billion euros ($19.30 billion) compared with EUR16.7 billion in the prior year, representing a rise of 9.4% on a reported basis and a 8.3% increase on a like-for-like basis.
Growth was driven by Vinci's energies and concessions businesses, which grew on a reported basis by 15% and 16%, respectively, it said.
Vinci said its order book as of Sept. 30 had reached a record high of EUR63.3 billion, a 10% on-year increase.
The company raised its outlook for free cash flow, and now expects to achieve at least EUR4.5 billion in 2023 compared with previous expectation of the upper end of the EUR4.0 billion to EUR4.5 billion range.
The company backed its other 2023 guidance.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
October 26, 2023 12:34 ET (16:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track